Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Jul 11. pii: blood-2018-03-836601. doi: 10.1182/blood-2018-03-836601. [Epub ahead of print]

PMID:
29997223
2.

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson KC, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 May 22. doi: 10.1038/s41375-018-0037-9. [Epub ahead of print]

PMID:
29789651
3.

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Mar 29. doi: 10.1038/s41375-018-0116-y. [Epub ahead of print]

PMID:
29749396
4.

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.

Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG.

Leukemia. 2018 Mar 27. doi: 10.1038/s41375-018-0115-z. [Epub ahead of print] No abstract available.

PMID:
29749395
5.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.

Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8.

PMID:
29740809
6.

Widespread intronic polyadenylation diversifies immune cell transcriptomes.

Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, Munshi NC, Mayr C, Leslie CS.

Nat Commun. 2018 Apr 30;9(1):1716. doi: 10.1038/s41467-018-04112-z.

7.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV.

JCI Insight. 2018 Apr 19;3(8). pii: 98259. doi: 10.1172/jci.insight.98259. [Epub ahead of print]

8.

Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.

Xu Y, Deng S, Mao X, An G, Li Z, Wang Y, Fulciniti M, Ho M, Lin J, Sui W, Liu W, Zou D, Yi S, Huang W, Liu H, Lv R, Li J, Wang T, Du C, Munshi NC, Qiu L.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):422-430. doi: 10.1016/j.clml.2018.03.006. Epub 2018 Mar 15.

PMID:
29625927
9.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0067-3. [Epub ahead of print]

10.

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.

Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, Munshi NC, Anderson KC.

Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0062-8. [Epub ahead of print]

PMID:
29487385
11.

Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells.

Pal J, Nanjappa P, Kumar S, Shi J, Buon L, Munshi NC, Shammas MA.

J Gastroenterol Hepatol Res. 2017;6(1):2286-2295. doi: 10.17554/j.issn.2224-3992.2017.06.687. Epub 2017 Feb 21.

12.

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD Jr, Usmani SZ, Wallace PK, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2018 Apr;24(4):641-648. doi: 10.1016/j.bbmt.2017.12.774. Epub 2017 Dec 11. Review.

PMID:
29242112
13.

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.

Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, Alexandrov LB, Fullam A, Martincorena I, Dawson KJ, Angelopoulos N, Samur MK, Szalat R, Zamora J, Tarpey P, Davies H, Corradini P, Anderson KC, Minvielle S, Neri A, Avet-Loiseau H, Keats J, Campbell PJ, Munshi NC, Bolli N.

Leukemia. 2018 Apr;32(4):1044-1048. doi: 10.1038/leu.2017.345. Epub 2017 Dec 6. No abstract available.

14.

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson K, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC.

Leukemia. 2017 Dec 6. doi: 10.1038/leu.2017.344. [Epub ahead of print]

PMID:
29209042
15.

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC.

Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.

16.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.

Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Apr;32(4):1003-1015. doi: 10.1038/leu.2017.336. Epub 2017 Nov 21.

17.

Castleman Disease.

van Rhee F, Munshi NC.

Hematol Oncol Clin North Am. 2018 Feb;32(1):xiii-xiv. doi: 10.1016/j.hoc.2017.10.001. No abstract available.

PMID:
29157623
18.

Diagnosis of Castleman Disease.

Szalat R, Munshi NC.

Hematol Oncol Clin North Am. 2018 Feb;32(1):53-64. doi: 10.1016/j.hoc.2017.09.005. Review.

PMID:
29157619
19.

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.

Cetin AE, Stevens MM, Calistri NL, Fulciniti M, Olcum S, Kimmerling RJ, Munshi NC, Manalis SR.

Nat Commun. 2017 Nov 20;8(1):1613. doi: 10.1038/s41467-017-01593-2.

20.

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.

Bae J, Hideshima T, Zhang GL, Zhou J, Keskin DB, Munshi NC, Anderson KC.

Leukemia. 2018 Mar;32(3):752-764. doi: 10.1038/leu.2017.316. Epub 2017 Nov 1.

21.

Logic programming reveals alteration of key transcription factors in multiple myeloma.

Miannay B, Minvielle S, Roux O, Drouin P, Avet-Loiseau H, Guérin-Charbonnel C, Gouraud W, Attal M, Facon T, Munshi NC, Moreau P, Campion L, Magrangeas F, Guziolowski C.

Sci Rep. 2017 Aug 23;7(1):9257. doi: 10.1038/s41598-017-09378-9.

22.

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F.

J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.

PMID:
28686535
23.

Nucleotide excision repair is a potential therapeutic target in multiple myeloma.

Szalat R, Samur MK, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, Wen K, Kumar S, Perini T, Calkins AS, Reznichenko E, Chauhan D, Tai YT, Shammas MA, Anderson KC, Fermand JP, Arnulf B, Avet-Loiseau H, Lazaro JB, Munshi NC.

Leukemia. 2018 Jan;32(1):111-119. doi: 10.1038/leu.2017.182. Epub 2017 Jun 7.

24.

Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.

Bolli N, Barcella M, Salvi E, D'Avila F, Vendramin A, De Philippis C, Munshi NC, Avet-Loiseau H, Campbell PJ, Mussetti A, Carniti C, Maura F, Barlassina C, Corradini P, Montefusco V.

Cancer. 2017 Oct 1;123(19):3701-3708. doi: 10.1002/cncr.30777. Epub 2017 May 23.

PMID:
28542843
25.

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC.

Clin Cancer Res. 2017 Sep 1;23(17):5225-5237. doi: 10.1158/1078-0432.CCR-17-0263. Epub 2017 Apr 25.

PMID:
28442502
26.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

PMID:
28428191
27.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM.

Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025.

28.

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC.

Clin Cancer Res. 2017 Aug 1;23(15):4280-4289. doi: 10.1158/1078-0432.CCR-16-2692. Epub 2017 Mar 7.

29.

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, Munshi NC, Tai YT, Anderson KC.

Clin Cancer Res. 2017 Aug 1;23(15):4290-4300. doi: 10.1158/1078-0432.CCR-16-3192. Epub 2017 Mar 1.

PMID:
28249894
30.

Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis.

Shapiro M, Nandi B, Gonzalez G, Prabhala RH, Mashimo H, Huang Q, Frank NY, Munshi NC, Gold JS.

Oncoimmunology. 2016 Dec 7;6(1):e1261776. doi: 10.1080/2162402X.2016.1261776. eCollection 2017.

31.

Gene Expression Profiles in Myeloma: Ready for the Real World?

Szalat R, Avet-Loiseau H, Munshi NC.

Clin Cancer Res. 2016 Nov 15;22(22):5434-5442. doi: 10.1158/1078-0432.CCR-16-0867. Review.

32.

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC.

Blood. 2017 Apr 20;129(16):2233-2245. doi: 10.1182/blood-2016-06-724831. Epub 2017 Jan 17.

33.

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC.

Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12.

34.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

35.

Review of siltuximab in the treatment of multicentric Castleman's disease.

Sarosiek S, Shah R, Munshi NC.

Ther Adv Hematol. 2016 Dec;7(6):360-366. Epub 2016 Jun 23. Review.

36.

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.

Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T, Joo J, Kong SY, Szalat RE, Richardson PG, Munshi NC, Dorfman DM, Anderson KC.

Oncotarget. 2016 Nov 22;7(47):77326-77341. doi: 10.18632/oncotarget.12643.

37.

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM.

JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.

38.

Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages.

Nandi B, Shapiro M, Samur MK, Pai C, Frank NY, Yoon C, Prabhala RH, Munshi NC, Gold JS.

Oncoimmunology. 2016 May 24;5(8):e1189052. doi: 10.1080/2162402X.2016.1189052. eCollection 2016 Aug.

39.

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC.

Blood Cancer J. 2016 Sep 2;6(9):e467. doi: 10.1038/bcj.2016.72.

40.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1609-1618. Epub 2016 Sep 1.

41.

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Gkotzamanidou M, Terpos E, Bamia C, Munshi NC, Dimopoulos MA, Souliotis VL.

Blood. 2016 Sep 1;128(9):1214-25. doi: 10.1182/blood-2016-01-691618. Epub 2016 Jul 21.

42.

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai YT, Anderson KC.

Blood. 2016 Sep 22;128(12):1590-603. doi: 10.1182/blood-2016-03-707547. Epub 2016 Jul 14.

43.

Corrigendum to "Genomic heterogeneity in multiple myeloma" [Curr. Opin. Genet. Dev. 30 (2015) 56-65].

Szalat R, Munshi NC.

Curr Opin Genet Dev. 2016 Apr;37:158. doi: 10.1016/j.gde.2016.02.003. Epub 2016 Mar 4. No abstract available.

PMID:
27321239
44.

Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches.

Szalat R, Munshi NC.

Am Soc Clin Oncol Educ Book. 2016;35:e442-8. doi: 10.14694/EDBK_159017. Review.

45.

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.

Lin J, Zhang W, Zhao JJ, Kwart AH, Yang C, Ma D, Ren X, Tai YT, Anderson KC, Handin RI, Munshi NC.

Blood. 2016 Jul 14;128(2):249-52. doi: 10.1182/blood-2016-03-704460. Epub 2016 May 18.

46.

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P.

Mol Cancer Ther. 2016 Jun;15(6):1364-75. doi: 10.1158/1535-7163.MCT-15-0985. Epub 2016 May 18.

47.

Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.

Wu SP, Pfeiffer RM, Ahn IE, Mailankody S, Sonneveld P, van Duin M, Munshi NC, Walker BA, Morgan G, Landgren O.

Clin Cancer Res. 2016 Aug 15;22(16):4039-44. doi: 10.1158/1078-0432.CCR-15-2366. Epub 2016 Feb 4.

48.

Deep Response in Multiple Myeloma: A Critical Review.

Fulciniti M, Munshi NC, Martinez-Lopez J.

Biomed Res Int. 2015;2015:832049. doi: 10.1155/2015/832049. Epub 2015 Dec 10. Review.

49.

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.

Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, Adamia S, Neri A, Hunter ZR, Treon SP, Anderson KC, Tassone P, Munshi NC.

Blood Cancer J. 2016 Jan 15;6:e380. doi: 10.1038/bcj.2015.106.

50.

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.

Eda H, Santo L, Wein MN, Hu DZ, Cirstea DD, Nemani N, Tai YT, Raines SE, Kuhstoss SA, Munshi NC, Kronenberg HM, Raje NS.

J Bone Miner Res. 2016 Jun;31(6):1225-34. doi: 10.1002/jbmr.2789. Epub 2016 Feb 19.

Supplemental Content

Loading ...
Support Center